nodes	percent_of_prediction	percent_of_DWPC	metapath
Eprosartan—AGTR1—dilated cardiomyopathy	0.59	1	CbGaD
Eprosartan—ABCC2—Spironolactone—dilated cardiomyopathy	0.176	0.594	CbGbCtD
Eprosartan—ABCC2—Furosemide—dilated cardiomyopathy	0.121	0.406	CbGbCtD
Eprosartan—CYP2C9—cardial valve—dilated cardiomyopathy	0.0116	0.622	CbGeAlD
Eprosartan—AGTR1—ACE Inhibitor Pathway—MAS1—dilated cardiomyopathy	0.00401	0.17	CbGpPWpGaD
Eprosartan—AGTR1—ACE Inhibitor Pathway—NR3C2—dilated cardiomyopathy	0.00312	0.132	CbGpPWpGaD
Eprosartan—AGTR1—cardiac ventricle—dilated cardiomyopathy	0.00204	0.109	CbGeAlD
Eprosartan—AGTR1—myocardium—dilated cardiomyopathy	0.00191	0.102	CbGeAlD
Eprosartan—Losartan—AGTR1—dilated cardiomyopathy	0.00191	0.634	CrCbGaD
Eprosartan—AGTR1—ACE Inhibitor Pathway—AGTR2—dilated cardiomyopathy	0.00168	0.0715	CbGpPWpGaD
Eprosartan—Cramps of lower extremities—Spironolactone—dilated cardiomyopathy	0.0015	0.0219	CcSEcCtD
Eprosartan—AGTR1—ACE Inhibitor Pathway—ACE—dilated cardiomyopathy	0.00144	0.061	CbGpPWpGaD
Eprosartan—Blood triglycerides increased—Furosemide—dilated cardiomyopathy	0.00135	0.0198	CcSEcCtD
Eprosartan—AGTR1—heart—dilated cardiomyopathy	0.00134	0.0714	CbGeAlD
Eprosartan—AGTR1—cardiac atrium—dilated cardiomyopathy	0.00114	0.0611	CbGeAlD
Eprosartan—Ataxia—Spironolactone—dilated cardiomyopathy	0.00111	0.0163	CcSEcCtD
Eprosartan—Losartan—ACE—dilated cardiomyopathy	0.0011	0.366	CrCbGaD
Eprosartan—Nephrolithiasis—Furosemide—dilated cardiomyopathy	0.0011	0.0161	CcSEcCtD
Eprosartan—Glycosuria—Furosemide—dilated cardiomyopathy	0.00109	0.016	CcSEcCtD
Eprosartan—Serum creatinine increased—Lisinopril—dilated cardiomyopathy	0.00108	0.0158	CcSEcCtD
Eprosartan—Gastritis—Spironolactone—dilated cardiomyopathy	0.00105	0.0153	CcSEcCtD
Eprosartan—ABCC2—ABC-family proteins mediated transport—ABCC9—dilated cardiomyopathy	0.000993	0.0422	CbGpPWpGaD
Eprosartan—Gout—Furosemide—dilated cardiomyopathy	0.000949	0.0139	CcSEcCtD
Eprosartan—Influenza-like symptoms—Lisinopril—dilated cardiomyopathy	0.00093	0.0136	CcSEcCtD
Eprosartan—AGTR1—ACE Inhibitor Pathway—AGT—dilated cardiomyopathy	0.000911	0.0387	CbGpPWpGaD
Eprosartan—Renal failure—Spironolactone—dilated cardiomyopathy	0.000895	0.0131	CcSEcCtD
Eprosartan—Otitis media—Lisinopril—dilated cardiomyopathy	0.000854	0.0125	CcSEcCtD
Eprosartan—Cramps of lower extremities—Furosemide—dilated cardiomyopathy	0.000814	0.0119	CcSEcCtD
Eprosartan—Urine output increased—Furosemide—dilated cardiomyopathy	0.000801	0.0117	CcSEcCtD
Eprosartan—Bladder pain—Furosemide—dilated cardiomyopathy	0.000801	0.0117	CcSEcCtD
Eprosartan—Diabetes mellitus—Furosemide—dilated cardiomyopathy	0.000739	0.0108	CcSEcCtD
Eprosartan—Viral infection—Lisinopril—dilated cardiomyopathy	0.000736	0.0108	CcSEcCtD
Eprosartan—Polyuria—Furosemide—dilated cardiomyopathy	0.000732	0.0107	CcSEcCtD
Eprosartan—Arthropathy—Lisinopril—dilated cardiomyopathy	0.000731	0.0107	CcSEcCtD
Eprosartan—Swelling—Furosemide—dilated cardiomyopathy	0.000729	0.0107	CcSEcCtD
Eprosartan—Vascular purpura—Furosemide—dilated cardiomyopathy	0.000719	0.0105	CcSEcCtD
Eprosartan—Gout—Lisinopril—dilated cardiomyopathy	0.000712	0.0104	CcSEcCtD
Eprosartan—AGTR1—Arf6 signaling events—ADRB2—dilated cardiomyopathy	0.000689	0.0293	CbGpPWpGaD
Eprosartan—Muscle spasms—Spironolactone—dilated cardiomyopathy	0.000684	0.01	CcSEcCtD
Eprosartan—Purpura—Furosemide—dilated cardiomyopathy	0.000667	0.00976	CcSEcCtD
Eprosartan—Ill-defined disorder—Spironolactone—dilated cardiomyopathy	0.00066	0.00966	CcSEcCtD
Eprosartan—Cystitis noninfective—Lisinopril—dilated cardiomyopathy	0.000649	0.00949	CcSEcCtD
Eprosartan—Hyponatraemia—Furosemide—dilated cardiomyopathy	0.000646	0.00944	CcSEcCtD
Eprosartan—Influenza like illness—Lisinopril—dilated cardiomyopathy	0.000645	0.00944	CcSEcCtD
Eprosartan—CYP2C9—heart—dilated cardiomyopathy	0.000643	0.0344	CbGeAlD
Eprosartan—Malaise—Spironolactone—dilated cardiomyopathy	0.000642	0.00939	CcSEcCtD
Eprosartan—Cystitis—Lisinopril—dilated cardiomyopathy	0.000642	0.00938	CcSEcCtD
Eprosartan—Blood creatinine increased—Furosemide—dilated cardiomyopathy	0.000602	0.00881	CcSEcCtD
Eprosartan—Bladder pain—Lisinopril—dilated cardiomyopathy	0.000601	0.00879	CcSEcCtD
Eprosartan—Discomfort—Spironolactone—dilated cardiomyopathy	0.000599	0.00876	CcSEcCtD
Eprosartan—Orthostatic hypotension—Furosemide—dilated cardiomyopathy	0.000587	0.00859	CcSEcCtD
Eprosartan—Hypokalaemia—Furosemide—dilated cardiomyopathy	0.000585	0.00856	CcSEcCtD
Eprosartan—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.000569	0.00832	CcSEcCtD
Eprosartan—Muscular weakness—Furosemide—dilated cardiomyopathy	0.000567	0.00829	CcSEcCtD
Eprosartan—Diabetes mellitus—Lisinopril—dilated cardiomyopathy	0.000555	0.00811	CcSEcCtD
Eprosartan—AGTR1—Arf6 trafficking events—ADRB2—dilated cardiomyopathy	0.000544	0.0231	CbGpPWpGaD
Eprosartan—Gastroenteritis—Lisinopril—dilated cardiomyopathy	0.000544	0.00796	CcSEcCtD
Eprosartan—Eczema—Lisinopril—dilated cardiomyopathy	0.000537	0.00785	CcSEcCtD
Eprosartan—AGTR1—Arf6 trafficking events—ITGB1—dilated cardiomyopathy	0.000526	0.0223	CbGpPWpGaD
Eprosartan—AGTR1—Peptide GPCRs—AGTR2—dilated cardiomyopathy	0.000519	0.0221	CbGpPWpGaD
Eprosartan—Somnolence—Spironolactone—dilated cardiomyopathy	0.000516	0.00755	CcSEcCtD
Eprosartan—Pollakiuria—Furosemide—dilated cardiomyopathy	0.000513	0.00751	CcSEcCtD
Eprosartan—Atrial fibrillation—Lisinopril—dilated cardiomyopathy	0.000509	0.00744	CcSEcCtD
Eprosartan—Hyperglycaemia—Furosemide—dilated cardiomyopathy	0.000501	0.00733	CcSEcCtD
Eprosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—ITGB1—dilated cardiomyopathy	0.0005	0.0213	CbGpPWpGaD
Eprosartan—Arthritis—Lisinopril—dilated cardiomyopathy	0.000496	0.00726	CcSEcCtD
Eprosartan—Renal failure—Furosemide—dilated cardiomyopathy	0.000487	0.00712	CcSEcCtD
Eprosartan—Hyponatraemia—Lisinopril—dilated cardiomyopathy	0.000484	0.00708	CcSEcCtD
Eprosartan—AGTR1—Peptide GPCRs—CXCR3—dilated cardiomyopathy	0.000483	0.0205	CbGpPWpGaD
Eprosartan—Osteoarthritis—Lisinopril—dilated cardiomyopathy	0.000482	0.00706	CcSEcCtD
Eprosartan—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.000479	0.007	CcSEcCtD
Eprosartan—Face oedema—Lisinopril—dilated cardiomyopathy	0.000466	0.00681	CcSEcCtD
Eprosartan—Urticaria—Spironolactone—dilated cardiomyopathy	0.000461	0.00675	CcSEcCtD
Eprosartan—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.000459	0.00672	CcSEcCtD
Eprosartan—AGTR1—GPCRs, Class A Rhodopsin-like—MAS1—dilated cardiomyopathy	0.000455	0.0193	CbGpPWpGaD
Eprosartan—Ataxia—Lisinopril—dilated cardiomyopathy	0.000454	0.00663	CcSEcCtD
Eprosartan—Blood creatinine increased—Lisinopril—dilated cardiomyopathy	0.000452	0.00661	CcSEcCtD
Eprosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—RPS6KB1—dilated cardiomyopathy	0.000445	0.0189	CbGpPWpGaD
Eprosartan—Orthostatic hypotension—Lisinopril—dilated cardiomyopathy	0.000441	0.00644	CcSEcCtD
Eprosartan—Visual impairment—Furosemide—dilated cardiomyopathy	0.000429	0.00627	CcSEcCtD
Eprosartan—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.000428	0.00626	CcSEcCtD
Eprosartan—Gastritis—Lisinopril—dilated cardiomyopathy	0.000427	0.00624	CcSEcCtD
Eprosartan—Asthma—Lisinopril—dilated cardiomyopathy	0.000417	0.0061	CcSEcCtD
Eprosartan—Tinnitus—Furosemide—dilated cardiomyopathy	0.000415	0.00607	CcSEcCtD
Eprosartan—Pruritus—Spironolactone—dilated cardiomyopathy	0.000411	0.00601	CcSEcCtD
Eprosartan—Angina pectoris—Lisinopril—dilated cardiomyopathy	0.000406	0.00594	CcSEcCtD
Eprosartan—Sweating increased—Lisinopril—dilated cardiomyopathy	0.000406	0.00594	CcSEcCtD
Eprosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—RAC1—dilated cardiomyopathy	0.000402	0.0171	CbGpPWpGaD
Eprosartan—Bronchitis—Lisinopril—dilated cardiomyopathy	0.000401	0.00586	CcSEcCtD
Eprosartan—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.000397	0.00581	CcSEcCtD
Eprosartan—Upper respiratory tract infection—Lisinopril—dilated cardiomyopathy	0.000388	0.00567	CcSEcCtD
Eprosartan—Dizziness—Spironolactone—dilated cardiomyopathy	0.000384	0.00562	CcSEcCtD
Eprosartan—Flatulence—Furosemide—dilated cardiomyopathy	0.000382	0.00558	CcSEcCtD
Eprosartan—Hyperglycaemia—Lisinopril—dilated cardiomyopathy	0.000376	0.0055	CcSEcCtD
Eprosartan—Muscle spasms—Furosemide—dilated cardiomyopathy	0.000372	0.00544	CcSEcCtD
Eprosartan—Depression—Lisinopril—dilated cardiomyopathy	0.000371	0.00542	CcSEcCtD
Eprosartan—Vomiting—Spironolactone—dilated cardiomyopathy	0.000369	0.0054	CcSEcCtD
Eprosartan—Rash—Spironolactone—dilated cardiomyopathy	0.000366	0.00536	CcSEcCtD
Eprosartan—Dermatitis—Spironolactone—dilated cardiomyopathy	0.000366	0.00535	CcSEcCtD
Eprosartan—Renal failure—Lisinopril—dilated cardiomyopathy	0.000365	0.00534	CcSEcCtD
Eprosartan—Neuropathy peripheral—Lisinopril—dilated cardiomyopathy	0.000364	0.00533	CcSEcCtD
Eprosartan—Headache—Spironolactone—dilated cardiomyopathy	0.000364	0.00532	CcSEcCtD
Eprosartan—Urinary tract infection—Lisinopril—dilated cardiomyopathy	0.000361	0.00528	CcSEcCtD
Eprosartan—Haematuria—Lisinopril—dilated cardiomyopathy	0.000354	0.00518	CcSEcCtD
Eprosartan—Epistaxis—Lisinopril—dilated cardiomyopathy	0.000351	0.00513	CcSEcCtD
Eprosartan—Sinusitis—Lisinopril—dilated cardiomyopathy	0.000349	0.0051	CcSEcCtD
Eprosartan—Vertigo—Furosemide—dilated cardiomyopathy	0.000348	0.00509	CcSEcCtD
Eprosartan—Nausea—Spironolactone—dilated cardiomyopathy	0.000345	0.00505	CcSEcCtD
Eprosartan—Bradycardia—Lisinopril—dilated cardiomyopathy	0.00034	0.00497	CcSEcCtD
Eprosartan—Rhinitis—Lisinopril—dilated cardiomyopathy	0.000335	0.00489	CcSEcCtD
Eprosartan—Pharyngitis—Lisinopril—dilated cardiomyopathy	0.000331	0.00484	CcSEcCtD
Eprosartan—Oedema peripheral—Lisinopril—dilated cardiomyopathy	0.000329	0.00481	CcSEcCtD
Eprosartan—Dry mouth—Furosemide—dilated cardiomyopathy	0.000322	0.00471	CcSEcCtD
Eprosartan—AGTR1—Allograft Rejection—IL10—dilated cardiomyopathy	0.000317	0.0135	CbGpPWpGaD
Eprosartan—Tinnitus—Lisinopril—dilated cardiomyopathy	0.000311	0.00455	CcSEcCtD
Eprosartan—Shock—Furosemide—dilated cardiomyopathy	0.000311	0.00455	CcSEcCtD
Eprosartan—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.000309	0.00452	CcSEcCtD
Eprosartan—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.000306	0.00447	CcSEcCtD
Eprosartan—Anorexia—Furosemide—dilated cardiomyopathy	0.000301	0.00441	CcSEcCtD
Eprosartan—Chills—Lisinopril—dilated cardiomyopathy	0.000299	0.00438	CcSEcCtD
Eprosartan—Hypotension—Furosemide—dilated cardiomyopathy	0.000295	0.00432	CcSEcCtD
Eprosartan—AGTR1—Allograft Rejection—FASLG—dilated cardiomyopathy	0.000295	0.0125	CbGpPWpGaD
Eprosartan—Flatulence—Lisinopril—dilated cardiomyopathy	0.000286	0.00419	CcSEcCtD
Eprosartan—Tension—Lisinopril—dilated cardiomyopathy	0.000285	0.00417	CcSEcCtD
Eprosartan—AGTR1—Allograft Rejection—FAS—dilated cardiomyopathy	0.000285	0.0121	CbGpPWpGaD
Eprosartan—Paraesthesia—Furosemide—dilated cardiomyopathy	0.000284	0.00415	CcSEcCtD
Eprosartan—Nervousness—Lisinopril—dilated cardiomyopathy	0.000282	0.00413	CcSEcCtD
Eprosartan—Back pain—Lisinopril—dilated cardiomyopathy	0.000281	0.00411	CcSEcCtD
Eprosartan—Somnolence—Furosemide—dilated cardiomyopathy	0.000281	0.00411	CcSEcCtD
Eprosartan—Muscle spasms—Lisinopril—dilated cardiomyopathy	0.000279	0.00408	CcSEcCtD
Eprosartan—Decreased appetite—Furosemide—dilated cardiomyopathy	0.000275	0.00402	CcSEcCtD
Eprosartan—Fatigue—Furosemide—dilated cardiomyopathy	0.000272	0.00398	CcSEcCtD
Eprosartan—Tremor—Lisinopril—dilated cardiomyopathy	0.000272	0.00398	CcSEcCtD
Eprosartan—Pain—Furosemide—dilated cardiomyopathy	0.00027	0.00395	CcSEcCtD
Eprosartan—Constipation—Furosemide—dilated cardiomyopathy	0.00027	0.00395	CcSEcCtD
Eprosartan—Ill-defined disorder—Lisinopril—dilated cardiomyopathy	0.00027	0.00394	CcSEcCtD
Eprosartan—Angioedema—Lisinopril—dilated cardiomyopathy	0.000265	0.00388	CcSEcCtD
Eprosartan—Malaise—Lisinopril—dilated cardiomyopathy	0.000262	0.00383	CcSEcCtD
Eprosartan—Vertigo—Lisinopril—dilated cardiomyopathy	0.000261	0.00382	CcSEcCtD
Eprosartan—Syncope—Lisinopril—dilated cardiomyopathy	0.000261	0.00381	CcSEcCtD
Eprosartan—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.00026	0.00381	CcSEcCtD
Eprosartan—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.000258	0.00378	CcSEcCtD
Eprosartan—Palpitations—Lisinopril—dilated cardiomyopathy	0.000257	0.00375	CcSEcCtD
Eprosartan—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.000255	0.00373	CcSEcCtD
Eprosartan—Cough—Lisinopril—dilated cardiomyopathy	0.000254	0.00371	CcSEcCtD
Eprosartan—Urticaria—Furosemide—dilated cardiomyopathy	0.000251	0.00367	CcSEcCtD
Eprosartan—Body temperature increased—Furosemide—dilated cardiomyopathy	0.00025	0.00365	CcSEcCtD
Eprosartan—Abdominal pain—Furosemide—dilated cardiomyopathy	0.00025	0.00365	CcSEcCtD
Eprosartan—Chest pain—Lisinopril—dilated cardiomyopathy	0.000247	0.00362	CcSEcCtD
Eprosartan—Arthralgia—Lisinopril—dilated cardiomyopathy	0.000247	0.00362	CcSEcCtD
Eprosartan—Myalgia—Lisinopril—dilated cardiomyopathy	0.000247	0.00362	CcSEcCtD
Eprosartan—Anxiety—Lisinopril—dilated cardiomyopathy	0.000247	0.0036	CcSEcCtD
Eprosartan—Discomfort—Lisinopril—dilated cardiomyopathy	0.000244	0.00357	CcSEcCtD
Eprosartan—AGTR1—Peptide ligand-binding receptors—CXCL2—dilated cardiomyopathy	0.000244	0.0104	CbGpPWpGaD
Eprosartan—AGTR1—Peptide ligand-binding receptors—AGTR2—dilated cardiomyopathy	0.000244	0.0104	CbGpPWpGaD
Eprosartan—AGTR1—Arf6 signaling events—EGFR—dilated cardiomyopathy	0.000243	0.0103	CbGpPWpGaD
Eprosartan—Dry mouth—Lisinopril—dilated cardiomyopathy	0.000242	0.00354	CcSEcCtD
Eprosartan—Shock—Lisinopril—dilated cardiomyopathy	0.000233	0.00341	CcSEcCtD
Eprosartan—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.000233	0.0034	CcSEcCtD
Eprosartan—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.000232	0.0034	CcSEcCtD
Eprosartan—Tachycardia—Lisinopril—dilated cardiomyopathy	0.000231	0.00338	CcSEcCtD
Eprosartan—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.000229	0.00335	CcSEcCtD
Eprosartan—AGTR1—Peptide ligand-binding receptors—CXCR3—dilated cardiomyopathy	0.000227	0.00964	CbGpPWpGaD
Eprosartan—Asthenia—Furosemide—dilated cardiomyopathy	0.000227	0.00332	CcSEcCtD
Eprosartan—Anorexia—Lisinopril—dilated cardiomyopathy	0.000226	0.00331	CcSEcCtD
Eprosartan—Pruritus—Furosemide—dilated cardiomyopathy	0.000224	0.00327	CcSEcCtD
Eprosartan—Hypotension—Lisinopril—dilated cardiomyopathy	0.000222	0.00324	CcSEcCtD
Eprosartan—Diarrhoea—Furosemide—dilated cardiomyopathy	0.000216	0.00316	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.000216	0.00316	CcSEcCtD
Eprosartan—Insomnia—Lisinopril—dilated cardiomyopathy	0.000214	0.00314	CcSEcCtD
Eprosartan—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.000213	0.00311	CcSEcCtD
Eprosartan—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.000211	0.00309	CcSEcCtD
Eprosartan—Somnolence—Lisinopril—dilated cardiomyopathy	0.000211	0.00308	CcSEcCtD
Eprosartan—Dizziness—Furosemide—dilated cardiomyopathy	0.000209	0.00306	CcSEcCtD
Eprosartan—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.000209	0.00305	CcSEcCtD
Eprosartan—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.000206	0.00301	CcSEcCtD
Eprosartan—Fatigue—Lisinopril—dilated cardiomyopathy	0.000204	0.00299	CcSEcCtD
Eprosartan—Pain—Lisinopril—dilated cardiomyopathy	0.000203	0.00297	CcSEcCtD
Eprosartan—Constipation—Lisinopril—dilated cardiomyopathy	0.000203	0.00297	CcSEcCtD
Eprosartan—Vomiting—Furosemide—dilated cardiomyopathy	0.000201	0.00294	CcSEcCtD
Eprosartan—Rash—Furosemide—dilated cardiomyopathy	0.000199	0.00291	CcSEcCtD
Eprosartan—Dermatitis—Furosemide—dilated cardiomyopathy	0.000199	0.00291	CcSEcCtD
Eprosartan—Headache—Furosemide—dilated cardiomyopathy	0.000198	0.0029	CcSEcCtD
Eprosartan—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.000195	0.00286	CcSEcCtD
Eprosartan—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.000194	0.00284	CcSEcCtD
Eprosartan—AGTR1—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	0.000191	0.00812	CbGpPWpGaD
Eprosartan—Urticaria—Lisinopril—dilated cardiomyopathy	0.000188	0.00275	CcSEcCtD
Eprosartan—Nausea—Furosemide—dilated cardiomyopathy	0.000188	0.00275	CcSEcCtD
Eprosartan—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.000187	0.00274	CcSEcCtD
Eprosartan—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.000187	0.00274	CcSEcCtD
Eprosartan—AGTR1—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.000178	0.00755	CbGpPWpGaD
Eprosartan—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.000175	0.00255	CcSEcCtD
Eprosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—TNF—dilated cardiomyopathy	0.000174	0.0074	CbGpPWpGaD
Eprosartan—AGTR1—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.000172	0.00731	CbGpPWpGaD
Eprosartan—Asthenia—Lisinopril—dilated cardiomyopathy	0.00017	0.00249	CcSEcCtD
Eprosartan—Pruritus—Lisinopril—dilated cardiomyopathy	0.000168	0.00245	CcSEcCtD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.000164	0.00696	CbGpPWpGaD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.000164	0.00696	CbGpPWpGaD
Eprosartan—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.000162	0.00237	CcSEcCtD
Eprosartan—Dizziness—Lisinopril—dilated cardiomyopathy	0.000157	0.00229	CcSEcCtD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.000152	0.00647	CbGpPWpGaD
Eprosartan—Vomiting—Lisinopril—dilated cardiomyopathy	0.000151	0.0022	CcSEcCtD
Eprosartan—Rash—Lisinopril—dilated cardiomyopathy	0.00015	0.00219	CcSEcCtD
Eprosartan—Dermatitis—Lisinopril—dilated cardiomyopathy	0.000149	0.00218	CcSEcCtD
Eprosartan—Headache—Lisinopril—dilated cardiomyopathy	0.000149	0.00217	CcSEcCtD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.000147	0.00626	CbGpPWpGaD
Eprosartan—Nausea—Lisinopril—dilated cardiomyopathy	0.000141	0.00206	CcSEcCtD
Eprosartan—AGTR1—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.000139	0.00592	CbGpPWpGaD
Eprosartan—AGTR1—G alpha (q) signalling events—AGT—dilated cardiomyopathy	0.000134	0.00568	CbGpPWpGaD
Eprosartan—AGTR1—Peptide ligand-binding receptors—AGT—dilated cardiomyopathy	0.000132	0.00561	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.000125	0.0053	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.000125	0.0053	CbGpPWpGaD
Eprosartan—AGTR1—Allograft Rejection—TNF—dilated cardiomyopathy	0.000121	0.00513	CbGpPWpGaD
Eprosartan—CYP2C9—Arachidonic acid metabolism—GPX1—dilated cardiomyopathy	0.00012	0.00511	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—dilated cardiomyopathy	0.00012	0.00508	CbGpPWpGaD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.000119	0.00507	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.000116	0.00492	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.000115	0.00487	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000112	0.00477	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.000112	0.00474	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.000112	0.00474	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.000104	0.00441	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—ADRB2—dilated cardiomyopathy	9.1e-05	0.00386	CbGpPWpGaD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	8.86e-05	0.00376	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—dilated cardiomyopathy	8.3e-05	0.00353	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	7.44e-05	0.00316	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	7.05e-05	0.00299	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	7.05e-05	0.00299	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	6.99e-05	0.00297	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—AGT—dilated cardiomyopathy	6.75e-05	0.00287	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	6.55e-05	0.00278	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—AGTR2—dilated cardiomyopathy	6.4e-05	0.00272	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—CXCL2—dilated cardiomyopathy	6.4e-05	0.00272	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	6.34e-05	0.0027	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—CXCR3—dilated cardiomyopathy	5.95e-05	0.00253	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—ADRB1—dilated cardiomyopathy	5.76e-05	0.00245	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	5.69e-05	0.00242	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	5.14e-05	0.00218	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—ADRB2—dilated cardiomyopathy	4.67e-05	0.00198	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PSEN2—dilated cardiomyopathy	4.26e-05	0.00181	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—RAC1—dilated cardiomyopathy	3.99e-05	0.0017	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—AGT—dilated cardiomyopathy	3.81e-05	0.00162	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—AGTR2—dilated cardiomyopathy	3.78e-05	0.00161	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CXCL2—dilated cardiomyopathy	3.78e-05	0.00161	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—RAC1—dilated cardiomyopathy	3.62e-05	0.00154	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CXCR3—dilated cardiomyopathy	3.51e-05	0.00149	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—AGT—dilated cardiomyopathy	3.46e-05	0.00147	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—ADRB1—dilated cardiomyopathy	3.4e-05	0.00145	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ANKRD1—dilated cardiomyopathy	3.31e-05	0.00141	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—TAZ—dilated cardiomyopathy	3.11e-05	0.00132	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—SDHA—dilated cardiomyopathy	2.82e-05	0.0012	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—ADRB2—dilated cardiomyopathy	2.76e-05	0.00117	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—RAF1—dilated cardiomyopathy	2.4e-05	0.00102	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	2.37e-05	0.00101	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	2.26e-05	0.000961	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—RAC1—dilated cardiomyopathy	2.14e-05	0.000909	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—AGT—dilated cardiomyopathy	2.05e-05	0.000869	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	1.72e-05	0.00073	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	1.67e-05	0.000711	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—EGFR—dilated cardiomyopathy	1.65e-05	0.0007	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	1.51e-05	0.00064	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—RAF1—dilated cardiomyopathy	1.42e-05	0.000603	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—EGFR—dilated cardiomyopathy	9.73e-06	0.000414	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GPX1—dilated cardiomyopathy	7.65e-06	0.000325	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CD36—dilated cardiomyopathy	7.45e-06	0.000316	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—AGT—dilated cardiomyopathy	6.71e-06	0.000285	CbGpPWpGaD
